From each FDA label

Do GLP-1s cause skin sensitivity or nerve pain?

Ozempic, Rybelsus/Ozempic tablets, Trulicity, Saxenda, Victoza and Byetta list it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Word for word

What each label says about skin sensitivity

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • In clinical trials evaluating patients with and without type 2 diabetes mellitus, Wegovy 7.2 mg injection dysesthesia was reported at a higher rate in the Wegovy 7.2 mg injection group (22%), compared to Wegovy 2.4 mg injection (6%) and placebo (0.3%).
  • Among 288 patients who experienced dysesthesia with Wegovy 7.2 mg injection, 2% permanently discontinued treatment, 8% had temporary interruption, and 23% had dose reduction; most subjects with these actions taken to Wegovy 7.2 mg injection (permanent discontinuation, temporary interruption, or dose reduction) recovered from the event.
  • Among patients who experienced dysesthesia with Wegovy 7.2 mg injection, 18% did not report recovering during the trial duration; in most of the patients who did not recover, the Wegovy dosage was unchanged and not discontinued.
  • Of these 38 patients, 17 (45%) subsequently reported recurrence of dysesthesia.

Label revised Jun 18, 2026. DailyMed

Zepbound

  • In a pool of Study 1 and 2, dysesthesia occurred more frequently among patients receiving Zepbound (5 mg 0.2%, 10 mg 0.2%, 15 mg 0.4%) than placebo (0.1%).

Label revised Aug 28, 2026. DailyMed

Mounjaro

  • In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to Mounjaro, adverse reactions reported with Mounjaro were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%).
  • In the pool of placebo-controlled clinical trials in adults, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with Mounjaro 5 mg, 10 mg, and 15 mg, respectively.
  • In a CV outcomes trial, 0.7% of Mounjaro-treated patients reported dysesthesia.

Label revised Aug 27, 2026. DailyMed

Foundayo

  • In a pool of Trials 1 and 2, dysesthesia was reported in 0.3% and 1% of patients treated with Foundayo 9 mg, and 17.2 mg, respectively, and 0.1% of patients receiving placebo.
  • No patients taking Foundayo 5.5 mg reported dysesthesia.

Label revised Jul 29, 2026. DailyMed

Ozempic, Rybelsus and Ozempic tablets, Trulicity, Saxenda, Victoza, Byetta: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Skin sensitivity and tingling on a GLP-1: common questions

Does Wegovy cause skin sensitivity or nerve pain?

Its FDA label: In clinical trials evaluating patients with and without type 2 diabetes mellitus, Wegovy 7.2 mg injection dysesthesia was reported at a higher rate in the Wegovy 7.2 mg injection group (22%), compared to Wegovy 2.4 mg injection (6%) and placebo (0.3%). Among 288 patients who experienced dysesthesia with Wegovy 7.2 mg injection, 2% permanently discontinued treatment, 8% had temporary interruption, and 23% had dose reduction; most subjects with these actions taken to Wegovy 7.2 mg injection (permanent discontinuation, temporary interruption, or dose reduction) recovered from the event.

Does Zepbound cause skin sensitivity or nerve pain?

Its FDA label: In a pool of Study 1 and 2, dysesthesia occurred more frequently among patients receiving Zepbound (5 mg 0.2%, 10 mg 0.2%, 15 mg 0.4%) than placebo (0.1%).

Does Mounjaro cause skin sensitivity or nerve pain?

Its FDA label: In a CV outcomes trial of 6,647 adults with type 2 diabetes mellitus and established CV disease exposed to Mounjaro, adverse reactions reported with Mounjaro were similar with the exception of dysesthesia (0.7%), decreased appetite (17%), constipation (13%), vomiting (12%), abdominal pain (10%), and fatigue (10%). In the pool of placebo-controlled clinical trials in adults, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with Mounjaro 5 mg, 10 mg, and 15 mg, respectively.

Does Foundayo cause skin sensitivity or nerve pain?

Its FDA label: In a pool of Trials 1 and 2, dysesthesia was reported in 0.3% and 1% of patients treated with Foundayo 9 mg, and 17.2 mg, respectively, and 0.1% of patients receiving placebo. No patients taking Foundayo 5.5 mg reported dysesthesia.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.